Skip to main content
Erschienen in: World Journal of Urology 9/2021

29.03.2021 | Original Article

A qualitative framework of non-selection factors for cytoreductive nephrectomy

verfasst von: Andrew W. Silagy, Kyrollis Attalla, Renzo G. Dinatale, Kate L. Weiss, Stanley Weng, Roy Mano, Skylar Iosepovici, Julian Marcon, Ed Reznik, Ritesh R. Kotecha, Robert J. Motzer, Martin H. Voss, Jonathan A. Coleman, A. Ari Hakimi, Paul Russo

Erschienen in: World Journal of Urology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cytoreductive nephrectomy (CN) benefits a subset of patients with metastatic renal cell carcinoma (mRCC), however proper patient selection remains complex and controversial. We aim to characterize urologists’ reasons for not undertaking a CN at a quaternary cancer center.

Methods

Consecutive patients with mRCC referred to MSKCC urologists for consideration of CN between 2009 and 2019 were included. Baseline clinicopathologic characteristics were used to compare patients selected or rejected for CN. The reasons cited for not operating and the alternative management strategies recommended were extrapolated. Using an iterative thematic analysis, a framework of reasons for rejecting CN was designed. Kaplan–Meier estimates tested for associations between the reasons for not undertaking a CN and overall survival (OS).

Results

Of 297 patients with biopsy-proven mRCC, 217 (73%) underwent CN and 80 (27%) did not. Median follow-up of patients alive at data cut-off was 27.3 months. Non-operative patients were older (p = 0.014), had more sites of metastases (p = 0.008), harbored non-clear cell histology (p = 0.014) and reduced performance status (p < 0.001). The framework comprised seven distinct themes for recommending non-operative management: two patient-fitness considerations and five oncological considerations. These considerations were associated with OS; four of the oncological factors conferred a median OS of less than 12 months (p < 0.001).

Conclusion

We developed a framework of criteria by which patients were deemed unsuitable candidates for CN. These new insights provide a novel perspective on surgical selection, could potentially be applicable to other malignancies and possibly have prognostic implications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
5.
Zurück zum Zitat Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417–427. https://doi.org/10.1056/NEJMoa1803675CrossRefPubMed Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417–427. https://​doi.​org/​10.​1056/​NEJMoa1803675CrossRefPubMed
9.
Zurück zum Zitat Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/jco.2008.21.4809CrossRefPubMed Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://​doi.​org/​10.​1200/​jco.​2008.​21.​4809CrossRefPubMed
11.
Zurück zum Zitat Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MAS, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P (2017) Management of small renal masses: american society of clinical oncology clinical practice guideline. J Clin Oncol 35(6):668–680. https://doi.org/10.1200/JCO.2016.69.9645CrossRefPubMed Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MAS, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P (2017) Management of small renal masses: american society of clinical oncology clinical practice guideline. J Clin Oncol 35(6):668–680. https://​doi.​org/​10.​1200/​JCO.​2016.​69.​9645CrossRefPubMed
14.
Zurück zum Zitat Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar LM, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong MdPhDI, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME Randomized Clinical Trial. JAMA oncology 5(2):164–170. https://doi.org/10.1001/jamaoncol.2018.5543CrossRefPubMed Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar LM, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong MdPhDI, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME Randomized Clinical Trial. JAMA oncology 5(2):164–170. https://​doi.​org/​10.​1001/​jamaoncol.​2018.​5543CrossRefPubMed
15.
Zurück zum Zitat Bhindi B, Graham J, Wells JC, Bakouny Z, Donskov F, Fraccon A, Pasini F, Lee JL, Basappa NS, Hansen A, Kollmannsberger CK, Kanesvaran R, Yuasa T, Ernst DS, Srinivas S, Rini BI, Bowman I, Pal SK, Choueiri TK, Heng DYC (2020) Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2020.04.038CrossRefPubMed Bhindi B, Graham J, Wells JC, Bakouny Z, Donskov F, Fraccon A, Pasini F, Lee JL, Basappa NS, Hansen A, Kollmannsberger CK, Kanesvaran R, Yuasa T, Ernst DS, Srinivas S, Rini BI, Bowman I, Pal SK, Choueiri TK, Heng DYC (2020) Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. https://​doi.​org/​10.​1016/​j.​eururo.​2020.​04.​038CrossRefPubMed
17.
Zurück zum Zitat Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R (2018) Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urol Oncol 36(12):526.e513-526.e518. https://doi.org/10.1016/j.urolonc.2018.08.018CrossRef Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R (2018) Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urol Oncol 36(12):526.e513-526.e518. https://​doi.​org/​10.​1016/​j.​urolonc.​2018.​08.​018CrossRef
Metadaten
Titel
A qualitative framework of non-selection factors for cytoreductive nephrectomy
verfasst von
Andrew W. Silagy
Kyrollis Attalla
Renzo G. Dinatale
Kate L. Weiss
Stanley Weng
Roy Mano
Skylar Iosepovici
Julian Marcon
Ed Reznik
Ritesh R. Kotecha
Robert J. Motzer
Martin H. Voss
Jonathan A. Coleman
A. Ari Hakimi
Paul Russo
Publikationsdatum
29.03.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 9/2021
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-021-03650-4

Weitere Artikel der Ausgabe 9/2021

World Journal of Urology 9/2021 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.